Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2003

View Archived Issues

Aerogen initiates phase II pulmonary amikacin study

AEterna updates pipeline status following Zentaris acquisition

Miravant presents novel porphyrins for the diagnosis and treatment of vascular disorders

BMS scientists prepare new MMP, TACE and/or aggrecanase inhibitors

Pyrimidine-based CDK inhibitors and their use claimed by AstraZeneca

Novel activators of KCNQ channels and their use in migraine, neuropathic pain, etc.

GSK researchers describe novel series of PPARalpha agonists

ARYx reports new anticholinergics with utility in urinary incontinence and COPD

CytRx grants option to PSMA for TranzFect adjuvant

Chiron to transfer SILCAAT study to trial investigators

DSMB recommends that phase III Thymitaq trial continue

InSite Vision finalizes ISV-401 phase III trial protocol

Novartis obtains rights to pirenzepine for myopia from Valley Forge

Vion executes clinical trials agreement for Triapine with NCI

FDA committee backs Aldurazyme efficacy

Another AlgoRx product advances to clinical trials

Molecular mechanisms underlying alpha7 nAChR-mediated neuroprotection

Structurally novel class of inhibitors of VEGFR kinase discovered by Schering AG/Novartis

Possible explanation for sildenafil-associated thrombotic conditions

Long-term effects of tranilast in oligoasthenozoospermia

Comparative neuroprotective properties of CHF-3381, lamotrigine and MK-801

Tacrolimus reported safe and effective in chronic actinic dermatitis

Good safety profile reported for zosuquidar plus doxorubicin in advanced tumors

Clinical benefits induced by celecoxib in coronary artery disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...